1、该刊只有国际刊号。

2、投稿方式：在线投稿。

3、官网网址：

https://journals.lww.com/dm/pages/default.aspx

（主办单位微信公众号信息）

4、投稿系统：

https://www.editorialmanager.com/dm/default2.aspx

5、官网邮箱：editor@digitmedicine.com

6、出刊日期：季刊，逢季末月出版。

7、官网信息：作者发表无需承担任何费用

8、主办单位微信公众号：大医二院学科建设与科研管理部

2026年4月23日星期四

《Digital Medicine》期刊2026年第一期正式上线！

【主办单位微信公众号信息】

大医二院学科建设与科研管理部 2026年4月1日

近日，由大连医科大学附属第二医院主办、国际数字医学会提供学术支持的 《Digital Medicine》期刊2026年第一期正式上线！

期刊简介

《Digital Medicine》(ISSN 2542-629X)是由大连医科大学附属第二医院主办的一本经过严格同行评议的在线连续出版期刊，以全英文形式出版，季刊发行。本刊实行开放获取（Open Access）模式，所有内容均可免费阅读、下载和传播。期刊面向全球发行，作者发表无需承担任何费用，包括稿件提交费、处理费、出版费及图片彩色印刷费均予免除。本刊实行严格的匿名同行评审制度，确保学术评价的公正性与学术诚信，致力于构建一个充满活力、兼具包容性的学术共同体，倡导思想多元，鼓励创新探索。

征稿范围

《Digital Medicine》 收录范围涵盖：医学影像研究、数字与信息技术、人类与数字解剖相关研究、计算机辅助设计/制造/分析技术在临床中的应用研究、人工智能应用、数字医院建设与管理、生物工程、放射诊断与放射治疗、区域医疗协同与信息资源共建共享数据库建设、远程医疗会诊与教育，以及其他相关分支学科。期刊优先发表具有临床价值及临床转化意义的文章。

欢迎投稿

目前期刊2026年第一期已正式上线，各项投稿通道持续开放。欢迎临床医生和科研工作者踊跃投稿！

投稿方式：https://www.editorialmanager.com/dm/default2.aspx本刊官网：https://journals.lww.com/dm/pages/default.aspx编辑部邮箱：editor@digitmedicine.com

Instructions for Authors

【官网信息】

The

Editorial Office is pleased to answer any questions you may have about

preparing your manuscript in accordance with our guidelines.

Email: editor@digitmedicine.com

AIMS AND SCOPE

Digital

Medicine, a publication of International Society of Digital Medicine,

and academically supported by Second Hospital of Dalian Medical

University, is a peer-reviewed online continuous publishing journal The

journal allows free access (Open Access) to its contents and permits

authors to self-archive final accepted version of the articles on any

OAI-compliant institutional / subject-based repository. The journal does

not charge for submission, processing or publication of manuscripts and

even for color reproduction of photographs.

The

scope of Digital Medicine covers the medical imaging research, digital

and information technology, human and digital anatomy related research,

computer-aided design/manufacturing/analysis technology in clinical

application research, artificial intelligence application, digital

hospital construction and management, bioengineering, radiological

diagnosis and radiotherapy, regional medical collaboration and

information resource sharing database construction, telemedicine

consultation and education and other sub-disciplines. Articles with

clinical interest and implications will be given preference.

ONLINE SUBMISSION

First-time Users

Please

click the Register button at

https://www.editorialmanager.com/dm/default2.aspx. Upon successful

registration, you will be sent an email providing your username and

password. Save this information for future reference.

Note:

If you have received an email from us with an assigned username and

password, or if you are a repeat user, do not register again. Once you

have an assigned username and password, you do not have to re-register.

Authors

Please

click the Login button from the menu at the top of the page and login

to the system as an author. Submit your manuscript according to the

author instructions. You will be able to track the process of your

manuscript through the system.

JOURNAL POLICIES

Duplicate Publication

Manuscripts

are reviewed for possible publication with the understanding that they

are being submitted only to the Digital Medicine and have not been

published, simultaneously submitted, or already accepted for publication

elsewhere. The Editorial team may subject any manuscript submitted for

consideration of publication in the Digital Medicine to

plagiarism-detection software.

This

does not preclude consideration of a manuscript that has been rejected

by another journal or a complete report that follows publication of

preliminary findings elsewhere, usually in the form of an abstract.

Copies of any possibly duplicate published material should be submitted

with the manuscript under consideration, with a statement in the cover

letter as to why the manuscript currently being submitted is not a

duplicate publication.

Disclosure of Conflicts

Authors

must state all possible conflicts of interest in the manuscript,

including financial, consultant, institutional and other relationships

that might lead to bias or a conflict of interest. If there is no

conflict of interest, this should also be explicitly stated as none

declared. All sources of funding should be acknowledged in the

manuscript.

All

relevant conflicts of interest and financial support and sponsorship

should be included on the title page of the manuscript with the heading

"Conflicts of interest" and "Financial support and sponsorship ".

For

example: "Conflicts of interest: *** is an Editor-in-Chief/Associate

Editor/Editorial Board Member of the journal. The article was subject to

the journal's standard procedures, with peer review handled

independently of this editor and his research groups. /A has received

honoraria from Company Z. B is currently receiving a grant (#12345) from

Organization Y, and is on the speaker's bureau for Organization X - the

CME organizers for Company A./There are no conflicts of interest."

"Financial support and sponsorship": This study was supported by grants from xxx."

A

financial disclosure section is part of the submission process and must

be completed by each author at first revision. This information is for

review by the Editors but will be published if relevant to the content

of the accepted manuscript.

The

primary purpose of the disclosure section is to determine whether

authors have received any commercial financial support that could create

a conflict of interest. In addition to monetary interests, a potential

for conflict of interest can exist whether or not an individual believes

that a relationship (such as dual commitments, competing interests, or

competing loyalties) affects his or her scientific judgment. Please

review ICMJE Uniform Requirements for Manuscripts Submitted to

Biomedical Journals at the following link:

http://www.icmje.org/conflicts-of-interest.

Studies in Humans and Animals

If

the work involves the use of human subjects, the author should ensure

that the work described has been carried out in accordance with The Code

of Ethics of the World Medical Association (Declaration of Helsinki)

for experiments involving humans. The manuscript should be in line with

the Recommendations for the Conduct, Reporting, Editing and Publication

of Scholarly Work in Medical Journals and aim for the inclusion of

representative human populations (sex, age and ethnicity) as per those

recommendations. The terms sex and gender should be used correctly.

Authors

should include a statement in the manuscript that informed consent was

obtained for experimentation with human subjects. The privacy rights of

human subjects must always be observed.

Authors

describing studies involving animals must have consulted the ‘Animal

Research: Reporting In Vivo Experiments’ (ARRIVE) 2.0 guidelines,

developed by the NC3Rs to improve standards of reporting, ensuring that

the data from animal experiments can be fully scrutinized and utilized.

Articles reporting in vivo experiments must adhere to the ARRIVE

Essential 10 checklist as a minimum, and we encourage authors to use the

full ARRIVE 2.0 checklist. The relevant information outlined in these

guidelines should be included in the appropriate section of the article.

All animal experiments should be carried out in accordance with the

U.K. Animals (Scientific Procedures) Act, 1986 and associated

guidelines, EU Directive 2010/63/EU for animal experiments, or the

National Institutes of Health guide for the care and use of Laboratory

animals (NIH Publications No. 8023, revised 1978) and the authors should

clearly indicate in the manuscript that such guidelines have been

followed. The sex of animals must be indicated, and where appropriate,

the influence (or association) of sex on the results of the study.

Ethics

When

reporting studies on human subjects, author should indicate whether the

procedures followed were in accordance with the ethical standards of

the responsible committee on human experimentation (institutional or

regional) and with the Declaration of Helsinki

(https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/).

For prospective studies involving human participants, authors are

expected to mention about approval of regional/national/institutional or

independent ethics committee or review board, obtaining informed

consent from adult research participants and obtaining assent for

children aged over 7 years participating in the trial. The age beyond

which assent would be required could vary as per regional and/or

national guidelines. Ensure confidentiality of subjects by desisting

from mentioning participants' names, initials or hospital numbers,

especially in illustrative material. When reporting experiments on

animals, indicate whether the institution's or a national research

council's guide for, or any national law on the care and use of

laboratory animals was followed.

Evidence

for approval by a local ethics committee (for both human as well as

animal studies) must be supplied by the authors on demand. Animal

experimental procedures should be as humane as possible, and the details

of anesthetics and analgesics used should be clearly stated. The

ethical standards of experiments must be in accordance with the

guidelines provided by the CPCSEA and World Medical Association

Declaration of Helsinki on Ethical Principles for Medical Research

Involving experimental animals and human beings, respectively. The

journal will not consider any paper which is ethically unacceptable. A

statement on ethics committee permission and ethical practices must be

included in all research articles under the "Methods" section.

We

reserve the right to decline publication of a paper even after it has

been accepted if it becomes apparent that there are serious problems

with the scientific content or violations of our publishing policies.

Protection of Patients' Rights to Privacy

Identifying

information should not be published in written descriptions,

photographs, sonograms, CT scans, etc., and pedigrees unless the

information is essential for scientific purposes and the patient (or

parent or guardian, wherever applicable) gives written informed consent

for publication. Authors should remove patients' names from figures

unless they have obtained written informed consent from the patients.

The journal abides by ICMJE guidelines: (1) Authors, not the journals

nor the publisher, need to have the patient consent form before the

publication related to patient privacy and have the form properly

archived by the author. (2) If the publication includes some facial

images that make the patients identifiable, a statement about the

patient's consent needs to be present in the manuscript.

Data Availability Statement

Digital

Medicine requires authors to include in any articles that report

results derived from research data to include a Data Availability

Statement. The provision of a Data Availability Statement will be

verified as a condition of publication. Data Availability Statements

should include information on where data supporting the results reported

in the article can be found including, where applicable, hyperlinks to

publicly archived datasets analyzed or generated during the study. Where

research data are not publicly available, this must be stated in the

manuscript along with any conditions for accessing the data. Data

Availability Statements must take one of the following forms (or a

combination of more than one if required for multiple types of research

data):

The

datasets generated during and/or analyzed during the current study are

available in the [NAME] repository, [PERSISTENT WEB LINK TO DATASETS]

The

datasets generated during and/or analyzed during the current study are

not publicly available due [REASON WHY DATA ARE NOT PUBLIC] but are

available from the corresponding author on reasonable request.

The

datasets generated during and/or analyzed during the current study are

available from the corresponding author on reasonable request.

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

All

data generated or analyzed during this study are included in this

published article [and its supplementary information files].

The

data that support the findings of this study are available from [third

party name] but restrictions apply to the availability of these data,

which were used under license for the current study, and so are not

publicly available. Data are however available from the authors upon

reasonable request and with permission of [third party name].

AUTHORSHIP

Digital

Medicine expects that each person listed as an author has participated

sufficiently in the intellectual content, the analysis of data, and/or

the writing of the manuscript to take public responsibility for it. Each

author must have reviewed the manuscript, believes it represents valid

work, and approves it for submission.

Moreover,

should the Editorial team request the data upon which the manuscript is

based, the authors shall provide the data. Each author’s specific

contributions to the work should be indicated; this information will be

published as a footnote to the paper. For example, the areas of

participation might include:

Participated in research design

Participated in the writing of the paper

Participated in the performance of the research

Contributed new reagents or analytic tools

Participated in data analysis

An

author may list more than one contribution, and more than one author

may have contributed to the same aspect of the work. Any change in

authorship/contributions after submission must be approved in writing by

all authors and submitted to the Editorial Office for final

consideration.

AI Announcement

Authors

are fully responsible for the content of their manuscript, even those

parts produced by GenAI. Authors who have used GenAI in their research

and the writing of manuscripts should provide an open, transparent, and

detailed description of the use of GenAI (including the name and version

of the GenAI tool, when it was used, how it was used, and the process

of using it, and, if necessary, annotations for AI-assisted contents

dealing with facts and opinions), and review of GenAI, following the

body of the text, before the references, or in the method section (e.g.,

the authors have reviewed and edited the GenAI-produced content, and

take full responsibility for the authenticity and accuracy of the

content of this paper). It is recommended that authors submit and

archive the GenAI-assisted sections (text, figures, programs, etc.) as

supplementary material so that reviewers and editors can judge the

accuracy, integrity,and originality of the paper.

Since

GenAI cannot meet the requirements for authorship as they cannot take

responsibility for the submitted work, GenAI -related products and

developing teams cannot be listed as the author of a paper.

GenAI

cannot be used to write an entire paper or a significant portion of a

paper (e.g., method, result and analysis, etc.). All content that falls

under the category of scientific contribution or intellectual labor

should be finished by the author. If the main content of the paper is

completed using GenAI, the editorial office will handle it as academic

misconduct.

Plagiarism

As

defined by the World Association of Medical Editors

(http://www.wame.org/resources/publication-ethics-policies-for-medical-journals),

plagiarism is the use of others' published and unpublished ideas or

words (or other intellectual property) without attribution or

permission, and presenting them as new and original rather than derived

from an existing source. The intent and effect of plagiarism is to

mislead the reader as to the contributions of the plagiarizer. This

applies whether the ideas or words are taken from abstracts, research

grant applications, Institutional Review Board applications, or

unpublished or published manuscripts in any publication format (print or

electronic).

Digital

Medicine is a member of CrossCheck by CrossRef and iThenticate.

iThenticate is a plagiarism screening service that verifies the

originality of content submitted before publication. iThenticate checks

submissions against millions of published research papers, and billions

of web content. Authors, researchers and freelancers can also use

iThenticate to screen their work before submission by visiting

http://www.ithenticate.com.

All

allegations of plagiarism are investigated in accordance with the

Committee on Publication Ethics (COPE) guidelines detailed at

https://publicationethics.org/files/u7140/plagiarism%20A.pdf. When

plagiarism is detected at any time before or after publication, the

journal editorial office will take appropriate action as directed by the

standards set forth by COPE. If plagiarism is found, the author, the

author's institution and funding agencies, and the original publication

will be notified. A statement noting the plagiarism, providing a

reference to the plagiarized material, and linking to the original paper

may follow. Depending on the extent of the plagiarism, the paper may

also be formally retracted. For additional information, please visit

http://www.publicationethics.org.

ENGLISH LANGUAGE ASSISTANCE

Appropriate

use of the English language is a requirement for publication in the

Digital Medicine. Authors having difficulty in writing in English who

submit manuscripts to international journals often receive negative

comments from referees or editors about the English-language usage in

their manuscripts, and these challenges can contribute to a decision to

reject a paper. To help reduce the possibility of such problems, we

strongly encourage such authors consider using Wolters Kluwer Author

Services**.

Wolters Kluwer Author Services

Wolters

Kluwer, in partnership with Editage, offers a unique range of editorial

services to help you prepare a submission-ready manuscript:

Premium Editing: Intensive language and structural editing of academic papers to increase chances of journal acceptance.

Advanced Editing: A complete language, grammar, and terminology check to give you a publication-ready manuscript.

Translation

with Editing: Write your paper in your native language and Wolters

Kluwer Author Services will translate it into English, as well as edit

it to ensure that it meets international publication standards.

Plagiarism Check: Helps ensure that your manuscript contains no instances of unintentional plagiarism.

Artwork

Preparation: Save precious time and effort by ensuring that your

artwork is viewed favorably by the journal without you having to incur

the additional cost of purchasing special graphics software.

For more information regarding Wolters Kluwer Author Services, please visit http://wkauthorservices.editage.com.

**Note

that the use of such a service is at the author's own expense and risk,

and does not guarantee that the article will be accepted.

PEER REVIEW

Digital

Medicine operates a double-blind external peer review process. Digital

Medicine invites worldwide experts in the relevant field to make a

double-blind peer review of manuscripts submitted by authors. Review

comments are fully considered to ensure the academic value of the

journal. The primary task of reviewers is to evaluate the validity of

the approach, the significance and originality of the finding, its

interest and timeliness to the scientific community, and the clarity of

the writing. A qualified peer reviewer should send his/her feedback

(even decline to review due to some reasons) as per the time frame of

the journal. All peer reviewers must maintain a strict and perpetual

confidentiality for the content of all manuscripts under their review

and for any related correspondences with BPG and/or the journal

editorial team. Reviewers must not share any part of the manuscript with

a third party or discuss its content with the authors of the manuscript

or any other person. Reviewers must not plagiarize or cite any of the

contents of a manuscript before the manuscript has been formally

published. Reviewers will decline participation in the peer review

process for any manuscript if a conflict of interest exists, including

interests related to the manuscript's authors, personal interests, or

academic or economic interests. If a conflict of interest becomes

apparent during the peer review process, the reviewer must inform the

Editorial Office immediately. The following reasons are adequate, alone

or in combination, for rejection of a manuscript for publication: (1)

The scientific content does not correspond to the journal's aims and

scope; (2) The research is not reasonably designed and the data are

inadequate to support proper explanations or conclusions; (3) Related

work has been previously published and only a few new points have been

added; (4) The article contains accumulated information that has been

previously published, with only few technical improvements; (5) The

article is expected to attract only a very small portion of the

journal's readership audience; (6) The article has been rejected

previously and resubmitted without adding any new valuable content.

Manuscripts

received from Editorial Board Members will be screened by the

Editor-in-Chief and sent to external peer reviewers. The Editorial Board

Members, who submit manuscripts to the journal as authors or

co-authors, will be excluded from publication decisions.

Manuscripts

received from Editor-in-Chief will be handled by the other

co-Editor-in-Chief or one of the Associate Editor of the journal and

will be sent to external peer reviewers. The contributing

Editor-in-Chief will be excluded from decision-making of his/her

manuscript.

Editors

are not involved in decisions about papers which they have written

themselves or have been written by family members or colleagues or

whoever relate to products or services in which the editor has an

interest. Any such submission is subject to the journal's standard

procedures, with peer review handled independently of the relevant

editor and their research groups.

Appeal

The

authors have the right to appeal if they have a genuine cause to

believe that the editorial board has wrongly rejected the paper. If the

authors wish to appeal against the editorial decision, they should email

the editorial office (email: editor@digitmedicine.com) explaining in

detail the reason for the appeal. The appeals will be acknowledged by

the editorial office and will be investigated in an unbiased manner. The

processing of appeals will be done within 6-8 weeks. While under

appeal, the said manuscript should not be submitted to other journals.

The final decision rests with the Editor-in-Chief of the journal. Second

appeals are not considered.

......

更多详见：

https://edmgr.ovid.com/dm/accounts/ifauth.htm